A pilot clinical trial found that oral cannabinoids may help reduce systemic inflammation and affect viral reservoir markers in people with HIV on antiretroviral therapy.
HIV clinicians, infectious disease researchers, PWH interested in complementary treatments, and cannabinoid researchers.
n=10 pilotOral cannabinoids showed effects on inflammation and viral reservoir markers in PWH on ART
What the researchers found
Oral cannabinoid administration in PWH on ART showed effects on systemic inflammation markers and HIV viral reservoir measurements, supporting larger studies of cannabinoids as adjunctive anti-inflammatory therapy in HIV.
Why it matters
Despite viral suppression with ART, chronic HIV infection causes persistent inflammation that contributes to non-AIDS comorbidities. Cannabinoids could address this residual inflammation as an adjunctive treatment.
The numbers in context
Ten people with HIV on ART were randomized (n=5 per group) to increasing doses of oral cannabinoids in this pilot trial (CTN PT028).
How the study worked
Pilot randomized clinical trial with 10 PWH on ART receiving escalating doses of oral cannabinoids.
Who was studied
People with HIV on antiretroviral therapy (10 participants randomized to two groups).
What this study cannot tell us
Very small sample size (n=10); pilot design not powered for definitive conclusions; short treatment duration; diverse cannabinoid dosing complicates interpretation.
How to read the evidence
Pilot RCT provides preliminary evidence; very small sample requires larger confirmatory trials.
When this study was published
Recent pilot trial in an emerging area of HIV-cannabinoid research.
The bigger picture
This pilot trial contributes to the growing investigation of cannabinoids as anti-inflammatory agents in chronic diseases where persistent inflammation drives morbidity despite standard treatment.
Replication
Pilot data; joins a small but growing body of cannabinoid-HIV inflammation research.
Funding
Not specified
Conflicts of interest
Not specified
Questions still open
- Which cannabinoid formulation is most anti-inflammatory?
- Could cannabinoids reduce cardiovascular risk in PWH?
- What is the optimal duration of cannabinoid treatment?
Read the original research
Effects of Oral Cannabinoids on Systemic Inflammation and Viral Reservoir Markers in People with HIV on Antiretroviral Therapy: Results of the CTN PT028 Pilot Clinical Trial.
Cells, 12(14)
Citation
Mboumba Bouassa, Ralph-Sydney; Comeau, Eve; Alexandrova, Yulia; Pagliuzza, Amélie; Yero, Alexis; Samarani, Suzanne; Needham, Judy; Singer, Joel; Lee, Terry; Bobeuf, Florian; Vertzagias, Claude; Sebastiani, Giada; Margolese, Shari; Mandarino, Enrico; Klein, Marina B; Lebouché, Bertrand; Routy, Jean-Pierre; Chomont, Nicolas; Costiniuk, Cecilia T; Jenabian, Mohammad-Ali. (2023). Effects of Oral Cannabinoids on Systemic Inflammation and Viral Reservoir Markers in People with HIV on Antiretroviral Therapy: Results of the CTN PT028 Pilot Clinical Trial.. Cells, 12(14). https://doi.org/10.3390/cells12141811